Abstract
We translated these laboratory findings to a single-arm, phaseII clinical study in which patients with previously untreatedstage III/IV follicular lymphoma were initially treated intominimal residual disease (MRD) state with a uniformchemotherapy regimen, PACE (prednisone/doxorubicin/cyclophosphamide/etoposide), a modified ProMACE regimen(cyclophosphamide/etoposide/doxorubicin/mechlorethamine/procarbazine plus high-dose methotrexate with leucovorin rescueand prednisone) without methotrexate.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
